Cholib Dosage/Direction for Use




Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
Secondary causes of hyperlipidaemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment (like oral oestrogens), alcoholism should be adequately treated, before Cholib therapy is considered and patients should be placed on a standard cholesterol and triglycerides-lowering diet which should be continued during treatment.
Posology: The recommended dose is one tablet per day. Grapefruit juice should be avoided (see Interactions).
Response to therapy should be monitored by determination of serum lipid values (total cholesterol (TC), LDL-C, triglycerides (TG)).
Elderly patients (≥ 65 years old): No dose adjustment is necessary. The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate < 60 mL/min/1.73 m2 where Cholib is contraindicated (see Contraindications).
Patients with renal impairment: Cholib is contraindicated in patients with moderate to severe renal insufficiency whose estimated glomerular filtration rate is < 60 mL/min/1.73 m2 (see Contraindications).
Cholib should be used with caution in patients with mild renal insufficiency whose estimated glomerular filtration rate is 60 to 89 mL/min/1.73 m2 (see Precautions).
Patients with hepatic impairment: Cholib has not been studied in patients with hepatic impairment and is therefore contraindicated in this population (see Contraindications).
Paediatric population: Cholib is contraindicated in children and adolescents up to 18 years old. (see Contraindications).
Method of administration: Each tablet should be swallowed whole with a glass of water. The tablets should not be crushed or chewed. They may be taken with or without food (see Pharmacology: Pharmacokinetics under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in